NCT00394381View on ClinicalTrials.gov

Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome, High Grade
Interventions
PROCEDURE

Infusion of autologous CIK cells

Autologous CIK cells will be infused at timed intervals after autologous transplant for AML for group 1 patients, and with or without some cytoreduction treatment for group 2 patients

Trial Locations (1)

169608

Singapore General Hospital, Singapore

All Listed Sponsors
collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

lead

Singapore General Hospital

OTHER

NCT00394381 - Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter